Drugs / SRT2104
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT01453491 | Feb 2012 → Mar 2013 | ulcerative colitis | Sirtris, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT01031108 | May 2010 → Oct 2011 | type 2 diabetes mellitus | Sirtris, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT00920660 | Apr → Jun 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00938275 | Jan → Mar 2009 | type 2 diabetes mellitus | Sirtris, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT00937872 | Nov → Dec 2008 | type 2 diabetes mellitus | Sirtris, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT00933530 | May → Nov 2008 | type 2 diabetes mellitus | Sirtris, a GSK Company | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT01702493 Comparator | Oct → Dec 2012 | psoriasis | Sirtris, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT01039909 Comparator | Jan → Feb 2011 | muscular atrophy | GlaxoSmithKline | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01014117 Comparator | Dec 2009 → May 2010 | infectious disease with sepsis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00964340 Comparator | Oct 2009 → Apr 2010 | muscular atrophy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00933062 Comparator | Mar → May 2009 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01154101 Comparator | Jun 2010 → Nov 2011 | psoriasis | Sirtris, a GSK Company | Completed | No outcome recorded |
| Phase 2 | NCT01018017 Comparator | Mar → Dec 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00937326 Comparator | Aug 2009 → Sep 2010 | type 2 diabetes mellitus | Sirtris, a GSK Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRT2104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01453491 ↗ |
| Action | Activate | “SRT2104 is a potent small molecule activator of SIRT1” NCT01014117 ↗ |
| Modality | Small molecule | “SRT2104 is a potent small molecule activator of SIRT1” NCT01014117 ↗ |
| Route | Oral | “single, oral doses of SRT2104 (250 mg, 500 mg, 1000 mg, 2000 mg)” NCT00920660 ↗ |
| Target | SIRT1 | “SRT2104 is a potent small molecule activator of SIRT1” NCT01014117 ↗ |